期刊文献+

LC-MS/MS Method for Determination of Megestrol in Human Plasma and Its Application in Bioequivalence Study 被引量:1

LC-MS/MS Method for Determination of Megestrol in Human Plasma and Its Application in Bioequivalence Study
下载PDF
导出
摘要 A rapid and highly selective liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the determination of megestrol in human plasma was described using medry- sone as internal standard (IS). Blood samples were collected from 20 healthy volunteers after oral ad- ministration of 160 mg megestrol acetate dispersible tablets. The analytes were extracted by liq- uid-liquid extraction procedure and separated on a hanbon lichrospher column with the mobile phase of methanol and water containing 0.1% formic acid and 20 mmol/L ammonium acetate (5:1, v/v). Positive ion electrospray ionization with multiple reaction-monitoring mode (MRM) was employed by monitor- ing the transitions m/z 385.5-325.4 and m/z 387.5-327.4 for megestrol and medrysone, respectively. Under the isocratic separation conditions, the chromatographic rim time was approximately 2.54 min for megestrol and 2.59 min for medrysone. The calibration curve range was from 0.5 to 200.0 ng/mL. The inter-batch and intra-batch precision and accuracy were less than 5.2% relative standard deviation (RSD) and 6.4% relative error (RE). The proposed method was successfully applied in the bioequivalence study of megestrol acetate dispersible tablets. A rapid and highly selective liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the determination of megestrol in human plasma was described using medry- sone as internal standard (IS). Blood samples were collected from 20 healthy volunteers after oral ad- ministration of 160 mg megestrol acetate dispersible tablets. The analytes were extracted by liq- uid-liquid extraction procedure and separated on a hanbon lichrospher column with the mobile phase of methanol and water containing 0.1% formic acid and 20 mmol/L ammonium acetate (5:1, v/v). Positive ion electrospray ionization with multiple reaction-monitoring mode (MRM) was employed by monitor- ing the transitions m/z 385.5-325.4 and m/z 387.5-327.4 for megestrol and medrysone, respectively. Under the isocratic separation conditions, the chromatographic rim time was approximately 2.54 min for megestrol and 2.59 min for medrysone. The calibration curve range was from 0.5 to 200.0 ng/mL. The inter-batch and intra-batch precision and accuracy were less than 5.2% relative standard deviation (RSD) and 6.4% relative error (RE). The proposed method was successfully applied in the bioequivalence study of megestrol acetate dispersible tablets.
出处 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2013年第6期912-916,共5页 华中科技大学学报(医学英德文版)
基金 supported by the Foundation of the Zhejiang Xianju Pharmaceutical Co. Ltd(China)
关键词 MEGESTROL BIOEQUIVALENCE liquid chromatography-tandem mass spectrometry megestrol bioequivalence liquid chromatography-tandem mass spectrometry
  • 相关文献

参考文献15

  • 1Logmans A, Mous HVH, Bontenbal M, et al. Results of curettage for postmenopausal vaginal bleeding in women treated with tamoxifen and megestrol acetate for progres- sive metastatic breast carcinoma. Eur J Obstet Gyn R B, 1994,56(3):173-176.
  • 2Jonat W, Howell A, Blomqvist C, et al. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Euro J Cancer, 1996,32(3):404-412.
  • 3Stuart NS, Warwick J, Blackledge GR, et al. A random- ised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Euro J Cancer, 1996,32(11): 1888-1892.
  • 4Licchetta A, Correale P, Migali C, et al. Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate. J Chemother, 2010,22(3) :201-204.
  • 5Mateen F, Jatoi A. Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clin Nutr, 2006,25(5):711-715.
  • 6Westman G, Bergman B, Albertsson M, et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. Euro J Cancer, 1999,35(4): 586-595.
  • 7De Conno F, Martini C, Zecca E, et al. Megestrol acetate for anorexia in patients with far-advanced cancer: a dou- ble-blind controlled clinical trial. Euro J Cancer, 1998,34(11):1705-1709.
  • 8Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, et al. Systematic review of megestrol acetate in the treat- ment of anorexia-cachxia syndrome. J Pain Sym Man, 2004,27(4):360-369.
  • 9Fietkau R, Riepl M, Kettner H, et al. Supportive use of magestrol acetate in patients with head and neck cancer during radio(chemo)therapy. Euro J Cancer, 1997,33(1): 75-79.
  • 10Chen HC, Leung SW, Wang C J, et al. Effect of megestrol acetate and prepulsid on nutritional improvement in pa- tients with head and neck cancers undergoing radiother- apy. Radiother Oncol, 1997,43(1):75-79.

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部